

Special Issue

Prodrug Applications for Targeted Cancer Therapy

Message from the Guest Editors

Targeted cancer therapies are a key part of modern oncology, with prodrugs offering promising strategies to enhance selectivity and reduce toxicity. Advances in prodrug design enable precise activation, addressing challenges like poor solubility, low permeability, and drug resistance. This Special Issue focuses on the latest progress in prodrug-based targeted cancer therapy, including design, synthesis, and evaluation in vitro and in vivo. Topics include tumor-selective activation, stimuli-responsive prodrugs, nanocarrier conjugates, resistance mechanisms, pharmacokinetics, clinical perspectives, and regulatory aspects. We invite original research, reviews, and short communications to explore prodrugs' role in next-generation cancer treatments and translational applications.

We look forward to your contributions.

Guest Editors

Prof. Dr. René C.-Gaudreault

Department of Molecular Medicine, Faculté de Médecine, Université Laval, Québec, QC, Canada

Dr. Atziri Corin Chavez Alvarez

Faculté de Pharmacie, Université Clermont Auvergne, Clermont-Ferrand, Auvergne-Rhône-Alpes, France

Deadline for manuscript submissions

31 July 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/248793

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).